Downregulation of CFTR promotes epithelial-to-mesenchymal transition and is associated with poor prognosis of breast cancer

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1833, Issue 12, 2013, Pages 2961-2969

  Zhang, Jie Ting ^a   Jiang, Xiao Hua ^a   Xie, Chen ^a   Cheng, Hong ^c   Da Dong, Jian ^a   Wang, Yan ^a   Fok, Kin Lam ^a   Zhang, Xiao Hu ^a   Sun, Ting Ting ^a   Tsang, Lai Ling ^a   Chen, Hao ^a,d   Sun, Xiao Juan ^d   Chung, Yiu Wa ^a   Cai, Zhi Ming ^d   Jiang, Wen Guo ^b   Chan, Hsiao Chang ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

Author keywords

Breast cancer; CFTR; Epithelial to mesenchymal transition (EMT); Prognosis; UPA

Indexed keywords

ANION CHANNEL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; MICRORNA; PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL INVASION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; METASTASIS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 84882968128     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2013.07.021     Document Type: Article

References (48)

1. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.
2. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J. Clin. Invest. 2009, 119:1417-1419.
3. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 2005, 17:548-558.
4. Papageorgis P., Lambert A.W., Ozturk S., Gao F., Pan H., Manne U., Alekseyev Y.O., Thiagalingam A., Abdolmaleky H.M., Lenburg M., Thiagalingam S. Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res. 2010, 70:968-978.
5. Ozdamar B., Bose R., Barrios-Rodiles M., Wang H.R., Zhang Y., Wrana J.L. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 2005, 307:1603-1609.
6. Huber M.A., Azoitei N., Baumann B., Grunert S., Sommer A., Pehamberger H., Kraut N., Beug H., Wirth T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest. 2004, 114:569-581.
7. Smith H.W., Marshall C.J. Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell Biol. 2010, 11:23-36.
8. McMahon B., Kwaan H.C. The plasminogen activator system and cancer. Pathophysiol. Haemost. Thromb. 2008, 36:184-194.
9. Cozzi P.J., Wang J., Delprado W., Madigan M.C., Fairy S., Russell P.J., Li Y. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum. Pathol. 2006, 37:1442-1451.
10. Kumano M., Miyake H., Muramaki M., Furukawa J., Takenaka A., Fujisawa M. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol. Oncol. 2009, 27:180-186.
11. Li X.F., Yan P.J., Shao Z.M. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 2009, 28:3937-3948.
12. Xie C., Jiang X.H., Zhang J.T., Sun T.T., Dong J.D., Sanders A.J., Diao R.Y., Wang Y., Fok K.L., Tsang L.L., Yu M.K., Zhang X.H., Chung Y.W., Ye L., Zhao M.Y., Guo J.H., Xiao Z.J., Lan H.Y., Ng C.F., Lau K.M., Cai Z.M., Jiang W.G., Chan H.C. CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer. Oncogene 2013, 32(18):2282-2291.
13. Collins F.S. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992, 256:774-779.
14. Neglia J.P., FitzSimmons S.C., Maisonneuve P., Schoni M.H., Schoni-Affolter F., Corey M., Lowenfels A.B. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N. Engl. J. Med. 1995, 332:494-499.
15. McWilliams R.R., Rabe K.G., Olswold C., De Andrade M., Petersen G.M. Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer 2005, 104:388-394.
16. Maisonneuve P., Marshall B.C., Knapp E.A., Lowenfels A.B. Cancer Risk in Cystic Fibrosis: A 20-Year Nationwide Study From the United States. J. Natl. Cancer Inst. 2013, 105(2):122-129.
17. Warren N., Holmes J.A., al-Jader L., West R.R., Lewis D.C., Padua R.A. Frequency of carriers of cystic fibrosis gene among patients with myeloid malignancy and melanoma. BMJ 1991, 302:760-761.
18. Qiao D., Yi L., Hua L., Xu Z., Ding Y., Shi D., Ni L., Song N., Wang Y., Wu H. Cystic fibrosis transmembrane conductance regulator (CFTR) gene 5T allele may protect against prostate cancer: a case-control study in Chinese Han population. J. Cyst. Fibros. 2008, 7:210-214.
19. Li Y., Sun Z., Wu Y., Babovic-Vuksanovic D., Cunningham J.M., Pankratz V.S., Yang P. Cystic fibrosis transmembrane conductance regulator gene mutation and lung cancer risk. Lung Cancer 2010, 70:14-21.
20. King J.D., Lee J., Riemen C.E., Neumann D., Xiong S., Foskett J.K., Mehta A., Muimo R., Hallows K.R. Role of binding and nucleoside diphosphate kinase A in the regulation of the cystic fibrosis transmembrane conductance regulator by AMP-activated protein kinase. J. Biol. Chem. 2012, 287:33389-33400.
21. Pagano M.A., Tibaldi E., Gringeri E., Brunati A.M. Tyrosine phosphorylation and liver regeneration: a glance at intracellular transducers. IUBMB Life 2012, 64:27-35.
22. - channel function. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 281:L71-L78.
23. Hunter M.J., Treharne K.J., Winter A.K., Cassidy D.M., Land S., Mehta A. Expression of wild-type CFTR suppresses NF-kappaB-driven inflammatory signalling. PLoS One 2010, 5:e11598.
24. DiMango E., Ratner A.J., Bryan R., Tabibi S., Prince A. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J. Clin. Invest. 1998, 101:2598-2605.
25. Ye L., Bokobza S., Li J., Moazzam M., Chen J., Mansel R.E., Jiang W.G. Bone morphogenetic protein-10 (BMP-10) inhibits aggressiveness of breast cancer cells and correlates with poor prognosis in breast cancer. Cancer Sci 2010, 101(10):2137-2144.
26. Guarino M. Epithelial-mesenchymal transition and tumour invasion. Int. J. Biochem. Cell Biol. 2007, 39:2153-2160.
27. Accurso F.J., Sontag M.K. Gene modifiers in cystic fibrosis. J. Clin. Invest. 2008, 118:839-841.
28. Bremer L.A., Blackman S.M., Vanscoy L.L., McDougal K.E., Bowers A., Naughton K.M., Cutler D.J., Cutting G.R. Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis. Hum. Mol. Genet. 2008, 17:2228-2237.
29. Sidenius N., Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 2003, 22:205-222.
30. Reuning U., Magdolen V., Wilhelm O., Fischer K., Lutz V., Graeff H., Schmitt M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int. J. Oncol. 1998, 13:893-906.
31. Vij N., Mazur S., Zeitlin P.L. CFTR is a negative regulator of NFkappaB mediated innate immune response. PLoS One 2009, 4:e4664.
32. Zhang Y., Li C., Zhang C., Tao B. Study on the chemical constituents of Buddleja purdomii. Zhong Yao Cai 2005, 28:994-995.
33. Roxo-Rosa M., Davezac N., Bensalem N., Majumder M., Heda G.D., Simas A., Penque D., Amaral M.D., Lukacs G.L., Edelman A. Proteomics techniques for cystic fibrosis research. J. Cyst. Fibros. 2004, 3(Suppl. 2):85-89.
34. Turashvili G., Bouchal J., Baumforth K., Wei W., Dziechciarkova M., Ehrmann J., Klein J., Fridman E., Skarda J., Srovnal J., Hajduch M., Murray P., Kolar Z. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007, 7:55.
35. Radvanyi L., Singh-Sandhu D., Gallichan S., Lovitt C., Pedyczak A., Mallo G., Gish K., Kwok K., Hanna W., Zubovits J., Armes J., Venter D., Hakimi J., Shortreed J., Donovan M., Parrington M., Dunn P., Oomen R., Tartaglia J., Berinstein N.L. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11005-11010.
36. Southey M.C., Batten L., Andersen C.R., McCredie M.R., Giles G.G., Dite G., Hopper J.L., Venter D.J. CFTR deltaF508 carrier status, risk of breast cancer before the age of 40 and histological grading in a population-based case-control study. Int. J. Cancer 1998, 79:487-489.
37. LeSimple P., Liao J., Robert R., Gruenert D.C., Hanrahan J.W. Cystic fibrosis transmembrane conductance regulator trafficking modulates the barrier function of airway epithelial cell monolayers. J. Physiol. 2010, 588:1195-1209.
38. Pruliere-Escabasse V., Fanen P., Dazy A.C., Lechapt-Zalcman E., Rideau D., Edelman A., Escudier E., Coste A. TGF-beta 1 downregulates CFTR expression and function in nasal polyps of non-CF patients. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 288:L77-L83.
39. Howe K.L., Wang A., Hunter M.M., Stanton B.A., McKay D.M. TGFbeta down-regulation of the CFTR: a means to limit epithelial chloride secretion. Exp. Cell Res. 2004, 298:473-484.
40. Estell K., Braunstein G., Tucker T., Varga K., Collawn J.F., Schwiebert L.M. Plasma membrane CFTR regulates RANTES expression via its C-terminal PDZ-interacting motif. Mol. Cell. Biol. 2003, 23:594-606.
41. Schwiebert L.M., Estell K., Propst S.M. Chemokine expression in CF epithelia: implications for the role of CFTR in RANTES expression. Am. J. Physiol. 1999, 276:C700-C710.
42. Chen J., Jiang X.H., Chen H., Guo J.H., Tsang L.L., Yu M.K., Xu W.M., Chan H.C. CFTR negatively regulates cyclooxygenase-2-PGE(2) positive feedback loop in inflammation. J. Cell. Physiol. 2012, 227:2759-2766.
43. Zeitlin P. Can curcumin cure cystic fibrosis?. N. Engl. J. Med. 2004, 351:606-608.
44. Mantovani A. Molecular pathways linking inflammation and cancer. Curr. Mol. Med. 2010, 10:369-373.
45. Rayet B., Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999, 18:6938-6947.
46. Smith H.W., Marshall C.J. Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell Biol. 2010, 11:23-36.
47. Malinowsky K., Bollner C., Hipp S., Berg D., Schmitt M., Becker K.F. UPA and PAI-1 analysis from fixed tissues - new perspectives for a known set of predictive markers. Curr. Med. Chem. 2010, 17:4370-4377.
48. Malinowsky K., Wolff C., Gundisch S., Berg D., Becker K. Targeted therapies in cancer - challenges and chances offered by newly developed techniques for protein analysis in clinical tissues. J. Cancer 2010, 2:26-35.